Literature DB >> 7964857

Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases.

S V Kaveri1, L Mouthon, M D Kazatchkine.   

Abstract

Mesh：

Substances：

Year:  1994        PMID： 7964857      PMCID： PMC1016714          DOI： 10.1136/jnnp.57.suppl.6

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  24 in total

1.  In vivo reduction of circulating C1q binding immune complexes by intravenous gammaglobulin administration.

Authors:  R Y Lin; S P Racis
Journal:  Int Arch Allergy Appl Immunol       Date:  1986

2.  Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia.

Authors:  D Engelhard; J L Waner; N Kapoor; R A Good
Journal:  J Pediatr       Date:  1986-01       Impact factor: 4.406

3.  Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody.

Authors:  S B Clarkson; J B Bussel; R P Kimberly; J E Valinsky; R L Nachman; J C Unkeless
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245

4.  Modulation of mononuclear phagocyte function by intravenous gamma-globulin.

Authors:  R P Kimberly; J E Salmon; J B Bussel; M K Crow; M W Hilgartner
Journal:  J Immunol       Date:  1984-02       Impact factor: 5.422

5.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

6.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Authors:  Y Sultan; F Rossi; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

7.  Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies.

Authors:  A Ruiz-Arguelles
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

8.  Idiotypic/antiidiotypic interactions in systemic lupus erythematosus: demonstration of oscillating levels of anti-DNA autoantibodies and reciprocal antiidiotypic activity in a single patient.

Authors:  M Zouali; A Eyquem
Journal:  Ann Immunol (Paris)       Date:  1983 May-Jun

9.  Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis.

Authors:  A Saoudi; V Hurez; Y de Kozak; J Kuhn; S V Kaveri; M D Kazatchkine; P Druet; B Bellon
Journal:  Int Immunol       Date:  1993-12       Impact factor: 4.823

10.  High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance.

Authors:  M Basta; P F Langlois; M Marques; M M Frank; L F Fries
Journal:  Blood       Date:  1989-07       Impact factor: 22.113
View more
  5 in total

1.  New therapeutic perspectives for demyelinating retrobulbar optic neuritis.

Authors:  B Currò Dossi; A Amadori; C Cirafisi; S Lorusso; M Pasquinelli; M G Piscaglia; A Ravasio
Journal:  Ital J Neurol Sci       Date:  1998-02

2.  A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  N Thompson; P Choudhary; R A Hughes; R M Quinlivan
Journal:  J Neurol       Date:  1996-03       Impact factor: 4.849

3.  Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections.

Authors:  H Basma; A Norrby-Teglund; A McGeer; D E Low; O El-Ahmedy; J B Dale; B Schwartz; M Kotb
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  In vivo modulation of cytokine synthesis by intravenous immunoglobulin.

Authors:  W A Sewell; M E North; R Cambronero; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

5.  Differential immunomodulation of T-cells by immunoglobulin replacement therapy in primary and secondary antibody deficiency.

Authors:  Tri Dinh; Jun Oh; Donald William Cameron; Seung-Hwan Lee; Juthaporn Cowan
Journal:  PLoS One       Date:  2019-10-15       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.